Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00747864 |
| Other study ID # |
14083 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
September 3, 2008 |
| Last updated |
July 21, 2010 |
| Start date |
April 2006 |
| Est. completion date |
January 2007 |
Study information
| Verified date |
July 2010 |
| Source |
University of Utah |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
United States: Institutional Review Board |
| Study type |
Observational
|
Clinical Trial Summary
S100B, a calcium-binding protein, is found predominantly in the central nervous system (CNS)
and is increased in CSF and blood after CNS injury. There are two objectives to this study.
1) To complement our previous study, is urine S100B concentration correlated with
gestational age in infants born at > 28 weeks gestation during the first week of life? 2) Is
the urine concentration of S100B affected by intracranial pathology in this gestational age
range? Elevation of urine concentration of S100B may be an indicator that the infant will
develop serious intracranial pathology and may allow for early initiation of treatment to
potentially decrease morbidity.
Description:
S100B is a low molecular weight calcium binding protein found predominantly in the central
nervous system (CNS), specifically astroglial cells.[1] S100B plays a role in
calcium-dependent information processing and intracellulary is involved in the regulation of
cytoskeleton and cell morphology.[1] S100B is secreted by astrocytes and exhibits dose
dependent extracellular cytokine functions. In tissue culture at nanomolar concentration,
S100B stimulates neuronal growth, development, and regeneration and protects against
degeneration. At micromolar concentration, S100B is neurotoxic [2] and stimulates apoptosis
potentially through interaction with RAGE receptor, by induction of NO synthase, and through
the caspase cascade.
The evidence to support the S100B's role in development and maturation of the CNS is that
S100B is differentially distributed in different cortical regions of the brain during fetal
development and increases in concentration during gestation.[3] It is postulated that early
in development, S100B stimulates glial cell proliferation while later it leads to extension
of neurites, regulation of fiber sprouting, formation/maintenance of synapses, and
maturation of glial cells.[1] Cord blood concentration of S100B has been shown to be
inversely related to gestational age between 27 to 42 weeks gestation.[4] Thirty term
infants (37-42 weeks) had mean cord blood S100B concentration of 0.47 ug/L (range 0-1.5ug/L)
while 28 preterm infants (27-36 weeks) had a mean cord blood concentration of 1.14ug/L
(range 0.5 and 2.7 ug/L). Higher serum concentration of S100B in preterm infants may be due
the physiologic increase noted during development and/or lack of integrity of the
blood-brain barrier.
S100B is released from damaged astroglial cells and may reflect neuronal damage.[5,6]
Concentration of S100B is elevated in cerebrospinal fluid (CSF) of adult patients within 48
hours after infarction and remains elevated for at least 7 days after the event.[6] S100B is
also elevated in CSF for the first 3 days after traumatic brain injury [7] and subarachnoid
hemorrhage.[8] Due to its low molecular weight, S100B readily crosses a dysfunctional
blood-brain barrier and serum concentration of S100B is significantly increased in adult
patients after traumatic brain injury [9], stroke [10], or cardiac arrest.[5] Serum S100B
rises for 2-4 days after brain trauma or infarct and its concentration correlates with size
of damage as identified by CT scan. [9,10] After cardiac arrest, serum S100B concentration
was statistically elevated by 30 minutes after initiation of CPR and continued to be
significantly elevated in those patients who later exhibited brain damage by CT scan or
neurological exam.[5] This significant elevation in serum S100B lasted for at least 7 days.
In addition, serum S100B concentration correlated with morbidity [9] and neurological
outcome.[10] While the t1/2 of S100B is ~2 hours in adults, persistently increased
concentration of S100B in serum indicates continuous release from damaged cells.
The most common CNS trauma for preterm infants is intraventricular hemorrhage (IVH).[11] IVH
originates in the microcirculation/capillary network of the germinal matrix. Altered
cerebral blood flow secondary to poor cerebral autoregulation or systemic hypo- or
hypertension, platelet and coagulation disturbances, infection, and decreased capillary
integrity and vascular support have been implicated in the pathogenesis of IVH. IVH is
graded (1-4) by extent of hemorrhage seen by ultrasound. In grade I IVH, the blood is
confined to the germinal matrix. In Grade II IVH, blood is present in the germinal matrix
and a small of blood is present in the ventricles. Grade III IVH occurs when the ventricles
are filled with blood and dilated. In Grade IV IVH, blood extends into the brain parenchyma
due to venous congestion of the terminal veins that border the lateral ventricles which
leads to white matter necrosis. Grades I and II IVH are not associated with an increase in
developmental abnormalities, but do not insure normalcy. Grades III and IV IVH (severe IVH)
are highly associated with developmental delay, specifically spastic hemiplegia affecting
the lower extremities more than the upper extremities due to the proximity of the hemorrhage
to the descending motor fibers, and may also affect intellect. IVH, both mild (grade 1-2)
and severe (grade 3-4) are rarely seen in infants with gestational age > 28 weeks due to the
developmental involution of vessels in the germinal matrix which is the source of this
hemorrhage.[11]
Due to its low molecular weight (10.5 kD) and high degree of solubility, S100B is excreted
through the kidneys. It has been detected in the first void urine of infants between 26-42
weeks gestation with the most preterm infant exhibiting the highest concentration of S100B
(3.17 ug/L).[12] Mean urine S100B concentration in term infants (n=60) was 0.07 ug/L. This
study is confounded by no mention of intracranial pathology, insufficient number of preterm
infants, and actual data was not shown. In another study, S100B was elevated in urine in
preterm infants (29-35 weeks gestation) with IVH (grade 2-4) at birth and continued to
increase over the subsequent 3 days when compared to control preterm infants.[13] The
severity of IVH significantly correlated with the concentration of S100B in the urine. The
highest level of S100B was seen in the five infants who died. An important limitation of the
above cited study is insufficient patient enrollment to allow for correlation of both
gestational age and presence of severe IVH on urine S100B concentration. Recently, we have
shown that urine concentration of S100B is not elevated in very preterm infants (23-28 weeks
gestation) without intracranial pathology.[pas abstract] However, very preterm infants with
severe IVH (grade 3-4) had significantly elevated urine concentration of S100B on day 1.[14]
The specific aims of this study are to establish baseline S100B concentration in the urine
of infants with gestational age > 28 weeks. In addition, the impact of intracranial
pathology, that is IVH in preterm infants, will be further investigated. In the previous
study, infants who developed necrotizing enterocolitis (NEC) had extremely high levels of
S100B in the first week of life. NEC affects preterm infants, mostly 26-32 weeks gestation,
and can result in death or markedly increased complications and prolonged length of stay.
Secondary analysis of infants in this study will investigate if the development of NEC is
significantly associated with a high concentration S100B in the urine. If this is true, one
theory to explain this finding is that infants who develop NEC had an event around the time
of birth that caused decrease intestinal perfusion allowing increased susceptibility to
development of NEC.
